Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
High levels of FASN — a gene tied to fat production — are linked to resistance to sunitinib and worse survival outcomes in advanced kidney cancer. But patients with high FASN expression appear to benefit more from the combo therapy avelumab plus axitinib. The findings suggest FASN could be a key biomarker for guiding treatment decisions in renal cell carcinoma.
A new study presented at IKCS: North America 2026 found that high expression of the FASN gene — involved in lipid (fat) production — is associated with resistance to sunitinib, a standard targeted therapy, and significantly shorter progression-free survival (PFS) in patients with advanced renal cell carcinoma (RCC). Importantly, patients with high FASN expression appeared to derive greater relative benefit from the combination of avelumab plus axitinib compared to sunitinib alone.
Researchers analyzed clinical and RNA-sequencing data from 743 patients enrolled in the phase 3 JAVELIN Renal 101 trial. In the sunitinib arm, PFS dropped as FASN expression increased, while the combination arm showed consistent PFS regardless of FASN levels — suggesting the combo therapy may overcome FASN-driven resistance.
By the Numbers:
Why it matters: FASN expression may capture a metabolic resistance profile not reflected in standard clinical risk tools, potentially helping oncologists identify which RCC patients should skip sunitinib in favor of immunotherapy-based combinations.